机构：[1]Department of Medical Laboratory, The General Hospital of Western Theater Command, Chengdu, Sichuan 610083,China[2]Institute of Microbiology, Sichuan Center for Disease Control and Prevention, Chengdu, Sichuan 610044, China[3]Biology Teaching and Research Group, Chengdu Experimental Foreign Languages School, Chengdu, Sichuan 611134,China[4]Department of Medical Laboratory, Affiliated Cancer Hospital of Chengdu Medical College, Chengdu SeventhPeople's Hospital, Chengdu, Sichuan 610231, China.
Lupus nephritis (LN) has a high incidence in systemic lupus erythematosus (SLE) patients, but there is a lack of sensitive predictive markers. The purpose of the study was to investigate the association between the CD4 +CD8 + double positive T (DPT) lymphocytes and LN. The study included patients with SLE without renal impairment (SLE-NRI), LN, nephritic syndrome (NS), or nephritis. Peripheral blood lymphocyte subsets were analyzed by flow cytometry. Biochemical measurements were performed with peripheral blood in accordance with the recommendations proposed by the National Center for Clinical Laboratories. The proportions of DPT cells in the LN group were significantly higher than that in the SLE-NRI group ( t=4.012, P<0.001), NS group ( t=3.240, P=0.001), and nephritis group ( t=2.57, P=0.011). In the LN group, the risk of renal impairment increased significantly in a DPT cells proportion-dependent manner. The risk of LN was 5.136 times (95% confidence interval, 2.115-12.473) higher in cases with a high proportion of DPT cells than those whose proportion of DPT cells within the normal range. These findings indicated that the proportion of DPT cells could be a potential marker to evaluate LN susceptibility, and the interference of NS and nephritis could be effectively excluded when assessing the risk of renal impairment during SLE with DPT cell proportion.
基金：
Natural Science
Foundation of Sichuan Province (Grant No.
2022NSFSC1415), the Special Project of Sichuan
Province Traditional Chinese Medicine Administration
(Grant No. 2020JC0124), the Management
Project of General Hospital of Western Theater
Command (Grants No. 2021-XZYG-C22 and 2021-
XZYG-C21), and the Spark Young Innovative Talent
Project of General Hospital of Western Theater
Command.
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2022]版：
大类|4 区医学
小类|4 区医学：研究与实验
最新[2023]版：
大类|4 区医学
小类|4 区医学：研究与实验
第一作者：
第一作者机构：[1]Department of Medical Laboratory, The General Hospital of Western Theater Command, Chengdu, Sichuan 610083,China
通讯作者：
通讯机构：[1]Department of Medical Laboratory, The General Hospital of Western Theater Command, Chengdu, Sichuan 610083,China[4]Department of Medical Laboratory, Affiliated Cancer Hospital of Chengdu Medical College, Chengdu SeventhPeople's Hospital, Chengdu, Sichuan 610231, China.[*1]Division of Cellular and Molecular Diagnostics, Department of Medical Laboratory, The General Hospital of Western Theater Command, 270 Rong Du Avenue, Jinniu District, Chengdu, Sichuan 610083, China
推荐引用方式(GB/T 7714)：
Chang Kai,Na Wanlin,Liu Chenxia,et al.Peripheral CD4 +CD8 + double positive T cells: A potential marker to evaluate renal impairment susceptibility during systemic lupus erythematosus[J].The Journal of Biomedical Research.2022,59-68.doi:10.7555/JBR.36.20220094.
APA：
Chang Kai,Na Wanlin,Liu Chenxia,Xu Hongxuan,Liu Yuan...&Jiang Zhongyong.(2022).Peripheral CD4 +CD8 + double positive T cells: A potential marker to evaluate renal impairment susceptibility during systemic lupus erythematosus.The Journal of Biomedical Research,,
MLA：
Chang Kai,et al."Peripheral CD4 +CD8 + double positive T cells: A potential marker to evaluate renal impairment susceptibility during systemic lupus erythematosus".The Journal of Biomedical Research .(2022):59-68
